Sarah Aebersold, Chief Human Resources Officer at BioLife Solutions Inc., has executed a stock sale totaling $130,770 during a period of notable market volatility. The transaction involved 5,771 shares, sold at $22.66 each, and was carried out under a Rule 10b5-1 trading plan. This sale, disclosed in a regulatory filing, aligns with a strategy to cover tax obligations tied to vested restricted stock.
This move occurs amid fluctuating stock performance for BioLife Solutions, which has recently faced a 9.1% dip over the past week, despite an impressive 37.3% gain over the past year. Following the transaction, Aebersold retains 80,094 shares, reflecting a sustained commitment to the company’s future.
Financially, BioLife Solutions continues to exhibit resilience, reporting $22.7 million in revenue for Q4 2024, surpassing analyst forecasts. The net loss for the quarter stood at $2.0 million, significantly lower than the projected $4.4 million. For the full year, total revenue reached $82.3 million (excluding $37.7 million from discontinued operations), with a net loss of $11.4 million.
The Cell Processing segment has been instrumental to growth, with a 7% increase in revenue during Q4, marking five consecutive quarters of expansion. Analysts remain optimistic, with price targets ranging from $30 to $33 per share, underscoring confidence in the company’s potential.
BioLife Solutions is also making strides in the cell and gene therapy sectors, with its biopreservation media integrated into 17 approved therapies. Looking ahead, the company forecasts revenue between $95.5 million and $99 million for 2025, signaling continued growth and innovation. This development solidifies BioLife’s position as a leader in its market and highlights its potential to create long-term value.